# José Baselga

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jose-baselga/

## Facts

| Field | Value |
| --- | --- |
| Citations | 117,948 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 143 |
| i10-index | 414 |
| OpenAlex ID | https://openalex.org/A5004300577 |
| ORCID iD | https://orcid.org/0000-0003-1361-4063 |
| Works | 1,383 |

## Researcher papers

Showing 12 of 21.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients](https://scholariq.org/papers/mutational-landscape-of-metastatic-cancer-revealed-from-prospective-clinical/)
- [OncoKB: A Precision Oncology Knowledge Base](https://scholariq.org/papers/oncokb-a-precision-oncology-knowledge-base/)
- [Systematic identification of genomic markers of drug sensitivity in cancer cells](https://scholariq.org/papers/systematic-identification-of-genomic-markers-of-drug-sensitivity-in-cancer-cells/)
- [Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition](https://scholariq.org/papers/circulating-breast-tumor-cells-exhibit-dynamic-changes-in-epithelial-and/)
- [AACR Project GENIE: Powering Precision Medicine through an International Consortium](https://scholariq.org/papers/aacr-project-genie-powering-precision-medicine-through-an-international/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.](https://scholariq.org/papers/phase-ii-study-of-weekly-intravenous-recombinant-humanized-anti-p185her2/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers](https://scholariq.org/papers/the-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.